(BIIB) Biogen - Ratings and Ratios
Multiple Sclerosis, Spinal Muscular Atrophy, Alzheimer’s, Biosimilars, Neurology
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 31.8% |
| Value at Risk 5%th | 51.0% |
| Relative Tail Risk | -2.65% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.50 |
| Alpha | 4.23 |
| CAGR/Max DD | -0.27 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.341 |
| Beta | 0.593 |
| Beta Downside | 0.415 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.35% |
| Mean DD | 34.81% |
| Median DD | 35.55% |
Description: BIIB Biogen December 19, 2025
Biogen (NASDAQ: BIIB) is a global biotech firm that discovers, develops, manufactures, and commercializes therapies for neurological and neuro-degenerative diseases, with a footprint across the United States, Europe, Asia and other regions.
Its core marketed portfolio includes multiple-sclerosis drugs (Tecfidera, Vumerity, Avonex, Plegridy, Tysabri), the SMA treatment Spinraza, the Friedreich’s ataxia candidate Skyclarys, ALS therapy Qalsody, and a suite of biosimilars (Benepali, Imraldi, Flixabi, Byooviz, Tofidence). In oncology, Biogen sells Rituxan, Rituxan Hycela, Gazyva, Ocrevus, and emerging anti-CD20 agents such as glofitamab.
Beyond current products, the company is advancing pipelines in MS, Alzheimer’s disease (notably lecanemab, which generated $1.1 billion in 2023 U.S. sales), Parkinson’s disease, and other neuro-psychiatric indications, while expanding its biosimilar franchise.
Key financial metrics (FY 2023): revenue $10.6 billion, R&D spend ≈ 22 % of revenue, and a diluted EPS of $3.21. In Q2 2024, Tecfidera net sales fell 12 % YoY, reflecting competitive pressure and the rollout of generic alternatives.
Sector drivers that materially affect Biogen’s outlook include the aging global population (projected to increase the prevalence of neuro-degenerative disorders by ~30 % over the next decade) and U.S. Medicare reimbursement reforms that tighten pricing for high-cost biologics.
For a data-rich, analyst-level deep-dive on Biogen’s valuation sensitivities, the ValueRay platform offers a transparent, model-backed view worth exploring.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (1.61b TTM) > 0 and > 6% of Revenue (6% = 599.2m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 1.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 56.55% (prev 14.63%; Δ 41.92pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 2.45b > Net Income 1.61b (YES >=105%, WARN >=100%) |
| Net Debt (2.73b) to EBITDA (3.49b) ratio: 0.78 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.72 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (147.1m) change vs 12m ago 0.82% (target <= -2.0% for YES) |
| Gross Margin 70.12% (prev 71.78%; Δ -1.67pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 34.72% (prev 33.93%; Δ 0.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.50 (EBITDA TTM 3.49b / Interest Expense TTM 260.0m) >= 6 (WARN >= 3) |
Altman Z'' 6.15
| (A) 0.19 = (Total Current Assets 8.94b - Total Current Liabilities 3.29b) / Total Assets 29.21b |
| (B) 0.71 = Retained Earnings (Balance) 20.60b / Total Assets 29.21b |
| (C) 0.09 = EBIT TTM 2.73b / Avg Total Assets 28.76b |
| (D) 1.85 = Book Value of Equity 20.39b / Total Liabilities 11.00b |
| Total Rating: 6.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.25
| 1. Piotroski 6.0pt |
| 2. FCF Yield 7.55% |
| 3. FCF Margin 22.81% |
| 4. Debt/Equity 0.36 |
| 5. Debt/Ebitda 0.78 |
| 6. ROIC - WACC (= 2.99)% |
| 7. RoE 9.25% |
| 8. Rev. Trend -41.22% |
| 9. EPS Trend -42.59% |
What is the price of BIIB shares?
Over the past week, the price has changed by -12.37%, over one month by -4.13%, over three months by +15.58% and over the past year by +16.42%.
Is BIIB a buy, sell or hold?
- Strong Buy: 13
- Buy: 4
- Hold: 20
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BIIB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 191 | 16.2% |
| Analysts Target Price | 191 | 16.2% |
| ValueRay Target Price | 170.6 | 3.8% |
BIIB Fundamental Data Overview January 13, 2026
P/E Forward = 11.8765
P/S = 2.7344
P/B = 1.5117
P/EG = 5.3979
Revenue TTM = 9.99b USD
EBIT TTM = 2.73b USD
EBITDA TTM = 3.49b USD
Long Term Debt = 6.29b USD (from longTermDebt, last quarter)
Short Term Debt = 1.75b USD (from shortTermDebt, last fiscal year)
Debt = 6.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.73b USD (from netDebt column, last quarter)
Enterprise Value = 30.15b USD (27.52b + Debt 6.59b - CCE 3.96b)
Interest Coverage Ratio = 10.50 (Ebit TTM 2.73b / Interest Expense TTM 260.0m)
EV/FCF = 13.24x (Enterprise Value 30.15b / FCF TTM 2.28b)
FCF Yield = 7.55% (FCF TTM 2.28b / Enterprise Value 30.15b)
FCF Margin = 22.81% (FCF TTM 2.28b / Revenue TTM 9.99b)
Net Margin = 16.11% (Net Income TTM 1.61b / Revenue TTM 9.99b)
Gross Margin = 70.12% ((Revenue TTM 9.99b - Cost of Revenue TTM 2.98b) / Revenue TTM)
Gross Margin QoQ = 64.29% (prev 64.23%)
Tobins Q-Ratio = 1.03 (Enterprise Value 30.15b / Total Assets 29.21b)
Interest Expense / Debt = 1.02% (Interest Expense 67.4m / Debt 6.59b)
Taxrate = 16.29% (90.8m / 557.3m)
NOPAT = 2.29b (EBIT 2.73b * (1 - 16.29%))
Current Ratio = 2.72 (Total Current Assets 8.94b / Total Current Liabilities 3.29b)
Debt / Equity = 0.36 (Debt 6.59b / totalStockholderEquity, last quarter 18.21b)
Debt / EBITDA = 0.78 (Net Debt 2.73b / EBITDA 3.49b)
Debt / FCF = 1.20 (Net Debt 2.73b / FCF TTM 2.28b)
Total Stockholder Equity = 17.38b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.59% (Net Income 1.61b / Total Assets 29.21b)
RoE = 9.25% (Net Income TTM 1.61b / Total Stockholder Equity 17.38b)
RoCE = 11.53% (EBIT 2.73b / Capital Employed (Equity 17.38b + L.T.Debt 6.29b))
RoIC = 9.65% (NOPAT 2.29b / Invested Capital 23.67b)
WACC = 6.66% (E(27.52b)/V(34.11b) * Re(8.05%) + D(6.59b)/V(34.11b) * Rd(1.02%) * (1-Tc(0.16)))
Discount Rate = 8.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.48%
[DCF Debug] Terminal Value 84.77% ; FCFF base≈2.07b ; Y1≈2.39b ; Y5≈3.34b
Fair Price DCF = 514.2 (EV 78.16b - Net Debt 2.73b = Equity 75.43b / Shares 146.7m; r=6.66% [WACC]; 5y FCF grow 17.62% → 2.90% )
EPS Correlation: -42.59 | EPS CAGR: -48.19% | SUE: -2.92 | # QB: 0
Revenue Correlation: -41.22 | Revenue CAGR: -2.83% | SUE: 0.86 | # QB: 3
EPS next Quarter (2026-03-31): EPS=3.52 | Chg30d=+0.035 | Revisions Net=-4 | Analysts=16
EPS next Year (2026-12-31): EPS=15.19 | Chg30d=-0.035 | Revisions Net=-1 | Growth EPS=+1.1% | Growth Revenue=-5.1%
Additional Sources for BIIB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle